REGENXBIO (RGNX) News Today $8.47 -0.07 (-0.82%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period National Bank of Canada FI Purchases Shares of 68,000 REGENXBIO Inc. (NASDAQ:RGNX)National Bank of Canada FI bought a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 68,000 shares of the biotechnoloDecember 15 at 4:03 AM | marketbeat.comREGENXBIO's (RGNX) "Outperform" Rating Reiterated at Royal Bank of CanadaDecember 14, 2024 | americanbankingnews.comREGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Rating of "Moderate Buy" from AnalystsDecember 12, 2024 | americanbankingnews.comREGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by AnalystsREGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and eleven have issued a buy recoDecember 12, 2024 | marketbeat.comRBC Capital Sticks to Its Buy Rating for RegenXBio (RGNX)December 11, 2024 | markets.businessinsider.comJacobs Levy Equity Management Inc. Lowers Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)Jacobs Levy Equity Management Inc. cut its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 41.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 89,218 shares of the biotechnology company's stock afDecember 9, 2024 | marketbeat.comRedmile Group LLC Has $51.33 Million Holdings in REGENXBIO Inc. (NASDAQ:RGNX)Redmile Group LLC grew its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 7.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,892,902 shares of the biotechnology company's stock aftDecember 5, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Makes New $643,000 Investment in REGENXBIO Inc. (NASDAQ:RGNX)Connor Clark & Lunn Investment Management Ltd. acquired a new stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 61,288 shares of the biotechnology company's stock, valued at approximately $6November 29, 2024 | marketbeat.com3 Best Stocks to Buy Now, 11/21/2024, According to Top AnalystsNovember 21, 2024 | msn.comBuy Rating on RegenXBio Driven by Positive RGX-202 Trial Results and Strong Approval ProspectsNovember 21, 2024 | markets.businessinsider.comRegenxbio price target lowered to $36 from $40 at H.C. WainwrightNovember 21, 2024 | markets.businessinsider.comHC Wainwright Issues Pessimistic Forecast for REGENXBIO (NASDAQ:RGNX) Stock PriceHC Wainwright cut their price objective on shares of REGENXBIO from $40.00 to $36.00 and set a "buy" rating on the stock in a research report on Thursday.November 21, 2024 | marketbeat.comLeerink Partnrs Increases Earnings Estimates for REGENXBIOREGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2027 earnings per share (EPS) estimates for shares of REGENXBIO in a report issued on Monday, November 18th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology companyNovember 21, 2024 | marketbeat.comChardan Capital Reiterates Buy Rating for REGENXBIO (NASDAQ:RGNX)Chardan Capital restated a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Wednesday.November 20, 2024 | marketbeat.comRegenXBio’s RGX-202: Promising DMD Therapy with Best-in-Class Potential and Strategic BLA PlansNovember 19, 2024 | markets.businessinsider.comPromising Initial Data and Favorable Regulatory Pathway Support Buy Rating for RegenXBio’s RGX-202 in DMD TreatmentNovember 19, 2024 | markets.businessinsider.comWhat's Going On With REGENXBIO Shares Monday?November 18, 2024 | benzinga.comRegenxbio initiates pivotal phase of Affinity Duchenne trial of RGX-202November 18, 2024 | markets.businessinsider.comPromising Developments in RegenXBio’s RGX-202 Program Drive Buy RatingNovember 18, 2024 | markets.businessinsider.comREGENXBIO (NASDAQ:RGNX) Sees Unusually-High Trading Volume - Time to Buy?REGENXBIO (NASDAQ:RGNX) Sees Strong Trading Volume - Time to Buy?November 18, 2024 | marketbeat.comREGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATANovember 18, 2024 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesREGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has earned an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendNovember 17, 2024 | marketbeat.comOptimistic Growth Potential for RegenXBio Amidst Delivery Challenges and Promising Gene Therapy AdvancesNovember 16, 2024 | markets.businessinsider.comRegenxbio assumed with an Overweight at Morgan StanleyNovember 16, 2024 | markets.businessinsider.comREGENXBIO (NASDAQ:RGNX) Shares Gap Up - What's Next?REGENXBIO (NASDAQ:RGNX) Shares Gap Up - Still a Buy?November 15, 2024 | marketbeat.comREGENXBIO's (RGNX) Overweight Rating Reaffirmed at Morgan StanleyMorgan Stanley reaffirmed an "overweight" rating and issued a $22.00 price target on shares of REGENXBIO in a report on Friday.November 15, 2024 | marketbeat.comREGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202November 14, 2024 | prnewswire.comHC Wainwright Increases Earnings Estimates for REGENXBIOREGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Research analysts at HC Wainwright upped their FY2024 EPS estimates for shares of REGENXBIO in a report released on Thursday, November 7th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will post earnings per share of ($4.92)November 11, 2024 | marketbeat.comREGENXBIO FY2024 EPS Estimate Reduced by Leerink PartnrsREGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Investment analysts at Leerink Partnrs reduced their FY2024 EPS estimates for REGENXBIO in a research report issued to clients and investors on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology companyNovember 11, 2024 | marketbeat.comAnalysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter ReportNovember 9, 2024 | finance.yahoo.comPromising Advancements and Key Catalysts Drive Buy Rating for RegenXBioNovember 8, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: RegenXBio (RGNX), Gossamer Bio (GOSS) and Monte Rosa Therapeutics (GLUE)November 8, 2024 | markets.businessinsider.comRegenXBio’s Promising Gene Therapy Advancements and Strategic Financial Growth: A Buy RecommendationNovember 8, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for RegenXBio (RGNX)November 8, 2024 | markets.businessinsider.comREGENXBIO (NASDAQ:RGNX) Shares Gap Up - Here's WhyREGENXBIO (NASDAQ:RGNX) Shares Gap Up - Here's What HappenedNovember 7, 2024 | marketbeat.comRegenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ...November 7, 2024 | sg.finance.yahoo.comRegenxbio sees cash and securities sufficient into 2026November 7, 2024 | markets.businessinsider.comREGENXBIO Inc. (RGNX) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comREGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational UpdatesNovember 6, 2024 | prnewswire.comRegenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of EarningsNovember 5, 2024 | finance.yahoo.comREGENXBIO to Participate in Upcoming Investor ConferencesNovember 4, 2024 | prnewswire.comREGENXBIO (RGNX) Set to Announce Quarterly Earnings on WednesdayREGENXBIO (NASDAQ:RGNX) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.comREGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational HighlightsOctober 30, 2024 | prnewswire.comAssenagon Asset Management S.A. Cuts Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)Assenagon Asset Management S.A. lessened its holdings in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 31.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 559,872 shares of the biotechnology company's stock after selling 256,512 shares during the period. AssenOctober 30, 2024 | marketbeat.comThe past five years for REGENXBIO (NASDAQ:RGNX) investors has not been profitableOctober 24, 2024 | uk.finance.yahoo.comREGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by BrokeragesREGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and ten have issued a buy rating on the companOctober 23, 2024 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan CapitalChardan Capital reaffirmed a "buy" rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Tuesday.October 22, 2024 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Trading Down 6.4% - Time to Sell?REGENXBIO (NASDAQ:RGNX) Stock Price Down 6.4% - Here's What HappenedOctober 21, 2024 | marketbeat.comRegenxbio presents positive Phase 2 data of ABBV-RGX-314 in wet AMDOctober 21, 2024 | markets.businessinsider.comREGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024October 21, 2024 | prnewswire.com Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address How to piss off your liberal friends… and profit from it (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now RGNX Media Mentions By Week RGNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGNX News Sentiment▼0.560.71▲Average Medical News Sentiment RGNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGNX Articles This Week▼65▲RGNX Articles Average Week Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EVO News ARQT News NRIX News RCUS News KNSA News IMCR News OCUL News MESO News NTLA News TVTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGNX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share REGENXBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGNX Stock Alerts